Could US Solve Drug Shortages With 'Heightened' M&A Scrutiny?
FDA's inter-agency drug shortage task force wants comments on whether new shortage prevention and mitigation policies should include closer examination of mergers and acquisitions that could create drug shortages.
You may also be interested in...
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.
Lauren Silvis will leave her post as chief of staff at the US FDA in the next several weeks, when she will be replaced by associate commissioner for strategic initiatives and external affairs Keagan Lenihan.
Moving more manufacturing to the US could help increase supply chain reliability, which could prevent or blunt shortages, an industry representative argues.